Overview of Presentations#
BioRestorative Therapies, Inc. (NASDAQ:BRTX) is set to present important data from its stem cell programs at the International Society for Cell & Gene Therapy Annual Meeting, taking place from May 6-9 in Dublin, Ireland. The company will have two presentations on May 6, highlighting advancements in their research.
Clinical Trial Insights#
Francisco Silva, the Founder and Chief Scientist, will share safety and efficacy data from the ongoing Phase 2 clinical trial focused on chronic lumbar disc disease. This trial is fully enrolled, meaning all participant spots have been filled, and aims to assess the effectiveness of their treatment.
Preclinical Research#
Later in the day, Michael Joyce, the Director of Research and Development, will present preclinical data related to the company’s exosome platform. Exosomes are tiny particles released from cells that can carry proteins and other molecules, potentially offering therapeutic benefits. His presentation will explore specific applications of these exosomes in treatment.
Company Developments#
BioRestorative specializes in creating therapeutic products using adult stem cells, particularly their lead candidate, BRTX-100. This treatment is derived from a patient’s own stem cells and is designed for non-surgical relief of painful lumbosacral disc disorders. Despite facing challenges with a significant drop in share price over the past year, analysts project a substantial revenue increase of nearly 291% by fiscal 2026. Additionally, the FDA has granted permission to investigate BRTX-100 for chronic cervical discogenic pain.
The company is also expanding its focus to include programs targeting obesity and metabolic disorders, utilizing brown adipose-derived stem cells. Recently, BioRestorative raised approximately $5 million through a public offering and announced a partnership with dermatologist Dr. David J. Goldberg to study the effects of its regenerative skincare products.